NCT04658134 is a NA clinical trial of Glycine in Morbid Obesity, sponsored by Singapore General Hospital.

Who is sponsoring NCT04658134?

NCT04658134 is sponsored by Singapore General Hospital.

What drugs are being tested in NCT04658134?

Interventions in NCT04658134: Glycine.

What condition does NCT04658134 study?

NCT04658134 studies Morbid Obesity, Glycine; Metabolic Disorder.

Is NCT04658134 still recruiting?

NCT04658134 is currently status unknown. Last updated 17 March 2021.

Last reviewed 2021-03-17 · How we verify

NCT04658134

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Glycine "Deficiency" and the Kinetics of Acylglycine in Morbid Obesity

Status unknown NA Last updated 17 March 2021

What this trial tests

NA trial testing Glycine in Morbid Obesity in 20 participants. Status unknown.

Timeline

20 January 2021

Primary endpoint
15 December 2021

15 December 2021

Quick facts

Lead sponsor	Singapore General Hospital
Phase	NA
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	other
Enrollment	20
Start date	20 January 2021
Primary completion	15 December 2021
Estimated completion	15 December 2021
Sites	1 location across Singapore

Drugs / interventions tested

Glycine (GLYCINE) — full drug profile →

Conditions studied

Morbid Obesity — all drugs for Morbid Obesity →
Glycine; Metabolic Disorder — all drugs for Glycine; Metabolic Disorder →

Sponsor

Singapore General Hospital

Who can join

Adults 21 to 65, any sex, with Morbid Obesity or Glycine; Metabolic Disorder. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study aims to evaluate the effects of oral glycine supplementation on plasma glycine concentration, intracellular glutathione (GSH) concentration, plasma acylglycine concentration, urine acylglycine concentration, and insulin resistance in subjects with morbid obesity. This is an open-labelled trial. 20 adults with morbid obesity will be recruited. Following screening and baseline metabolic evaluations, eligible subjects will be given oral glycine supplements for 14 ± 5 days. Upon completing glycine supplementation, subjects will return for their post-supplement metabolic assessment. The investigators hypothesize that oral glycine supplementation in morbidly obese patients normalizes plasma glycine concentration, increases intracellular GSH concentration, increases plasma and urinary acylglycine concentration, and improves insulin resistance.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Glycine promotes cardiomyocyte proliferation and heart regeneration via the GCN2/AKT signaling axis.
Wang F, Zhang X, Tang Y, He Y, et al · · 2026 · PMID 42094615 · DOI 10.7150/thno.127992
Metabolic impact of dietary glycine supplementation in individuals with severe obesity.
Tan HC, Hsu JW, Tai ES, Chacko S, et al · · 2025 · PMID 41107432 · DOI 10.1038/s41598-025-20511-x

Verify or expand the search:

Other trials of Glycine

Trials testing the same drug.

NCT04740580 — Glutathione, Brain Metabolism and Inflammation in Alzheimer's Disease · EARLY_PHASE1 · recruiting
NCT04703036 — Glutathione, Oxidative Stress and Mitochondrial Function in COVID-19 · EARLY_PHASE1 · terminated
NCT04443673 — Glycine Supplement for Severe COVID-19 · NA · terminated
NCT03493178 — Glutathione in Mild Cognitive Impairment · EARLY_PHASE1 · active not recruiting
NCT03180775 — Effects of Dietary Amino Acids on Serum and Macrophage Atherogenicity · NA · unknown

Other recruiting trials for Morbid Obesity

Currently open trials in the same condition.

NCT06689241 — Rivaroxaban Versus Enoxaparin for Prophylaxis of Venous Thromboembolism in Bariatric Surgery · NA · recruiting
NCT06413264 — Ultrasonography Guided Pneumoperitoneum for Laparoscopic Surgery in Morbidly Obese Patients · NA · recruiting
NCT07289555 — Tailored Stapled SADI-S: Initial Report and Preliminary Results · NA · recruiting
NCT07263269 — Comparing Dumping Symptoms and Quality of Life 6 Months After Sleeve Gastrectomy With or Without Transit Bipartition in · NA · active not recruiting
NCT06293703 — Effect of Limb Length Ratio on Roux-en-Y Gastric Bypass Outcomes (CLIMB II Study) · NA · recruiting

Other Singapore General Hospital trials

Trials by the same sponsor.

NCT07452159 — Diabetes In Asians at Risk in Youth · not yet recruiting
NCT07527247 — Improving Vaccine Protection for Older Adults · Phase 2 · recruiting
NCT07533188 — Patient Outcomes Following Kinematic and Functional Alignment in Robotic-Assisted Total Knee Arthroplasty With Randomize · NA · recruiting
NCT07042061 — Trial of Mobile External Defibrillator for Out-of-hospital Cardiac Arrest in Singapore. · NA · not yet recruiting
NCT07099040 — Community-based Multi-domain Intervention to Detect and Delay Cognitive Decline in Community-dwelling Older Adults: A Pi · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04658134 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Singapore General Hospital
Last refreshed: 17 March 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04658134.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing